MedPath

A trial to study the effects of prophylactic use of Tranexamic acid in reducing blood loss after normal vaginal delivery

Phase 3
Registration Number
CTRI/2017/07/009011
Lead Sponsor
AFMC
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
273
Inclusion Criteria

Age > 20 yrs

Term pregnancies >37 wks

Singleton pregnancies

Planned vaginal deliveries

Exclusion Criteria

Age <19 and >35 yrs

Pre eclampsia,multiple pregnancy,placental abnormalities

Instrumental deliveries

Any cardiovascular, renal, liver disorders

Any hematological , hemorrhagic disorders

H/o venous or arterial thrombosis

H/o use of LMWH or antiplatelet drugs

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Mean change in peripartum hemoglobin and hematocrit values in the two groups <br/ ><br>Timepoint: After 24 hrs of Delivery
Secondary Outcome Measures
NameTimeMethod
â?¢Requirement of use of additional uterotonic agents to control blood loss in the two groupsTimepoint: Within 24 hrs;To compare the incidence of PPH in control and test armTimepoint: Within first 6 hrs
© Copyright 2025. All Rights Reserved by MedPath